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ABSTRACT
Forty-two multidrug-resistant (MDR) Acineto-
bacter baumannii isolates were obtained during
outbreaks in a Korean hospital. The co-carriage
of blaOXA-23, blaOXA-51, blaPER-1 and armA was
observed in 23 isolates, and they were susceptible
only to colistin and minocycline. The MDR
A. baumannii isolates were found to belong to
sequence group 1 using sequence-based typing.
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Acinetobacter baumannii is increasingly becoming a
major nosocomial pathogen that causes a variety
of human infections. Nosocomial A. baumannii
strains have readily developed resistance to cur-
rently available antimicrobial agents by intrinsic
and acquired mechanisms. Carbapenems are the
most potent b-lactams against Gram-negative
bacteria and are most widely used for treatment
of multidrug-resistant (MDR) A. baumannii infec-
tions. However, intensive use of carbapenems has
facilitated the emergence of carbapenem-resistant
bacteria. A. baumannii strains that are resistant to
all antimicrobial agents, but susceptible only
to colistin, referred to as colistin-only-sensitive
bacteria, have been detected worldwide [1,2].
Between May and July 2007, hospital outbreaks
of MDR A. baumannii occurred in a tertiary
hospital, located in Gyungnam, Korea. As A. bau-
mannii isolates were resistant to all b-lactams,
including carbapenems, the patients infected by
MDR A. baumannii received colistin-based therapy
or carbapenems combined with aminoglycosides.
However, 13 of the 17 infected patients died, from
either septic shock (six patients) or a combination
of underlying diseases (seven patients). Consider-
ing the high rate of mortality of the infected
patients, antimicrobial susceptibilities of MDR
A. baumannii isolates were determined, to evaluate
alternative agents for treatment, and the resistance
mechanisms were investigated, to determine the
complexity of antimicrobial resistance.
In total, 42 non-duplicate imipenem-resistant
A. baumannii isolates (17 from the infected
patients and 25 from the colonized patients) were
collected during an outbreak of Acinetobacter
infections. The sites of the specimens were as
follows: 28 from sputum, four from wounds, three
from ascitic fluids, three from pleural fluids, two
from blood, and two from catheter tips. Genomic
species were identified by amplified ribosomal
DNA restriction analysis [3]. The antimicrobial
susceptibility test was performed by agar dilution
in Mueller–Hinton agar (Difco Laboratories,
Detroit, MI, USA) according to the guidelines of
the CLSI [4]. The 20 antimicrobial agents tested
are listed in Table 1. Imipenem-resistant A. bau-
mannii isolates were screened by a modified
Hodge test and an imipenem–EDTA double-disk
synergy test [5]. Genes coding for carbapenemas-
es were sought by PCR using primers specific for
the genes blaVIM-like [6], blaIMP-like [6], blaSIM-1 [7],
blaOXA-23-like [8], blaOXA-24-like [8], blaOXA-51-like [9]
and blaOXA-58 [9]. PCR products were sequenced
to identify the specific genes. The presence
of ISAba1 inserted upstream of blaOXA-51 and
blaOXA-23 was sought via PCR, as previously
described [10]. PCR amplification with the prim-
ers for blaPER-1 was performed [11]. The primers
for armA, rmtA, rmtB and rmtC were used
to detect 16S rRNA methylase genes [12–15].
Genomic DNA was digested with ApaI (Roche
Diagnostics, Mannheim, Germany) and separated
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on a 1.0% agarose gel, using a contour-clamped
homogeneous-field apparatus (CHEF DRIII sys-
tems; Bio-Rad Laboratories, Hercules, CA, USA)
in 0.5 · TBE buffer [16]. PCR for ompA, csuE and
blaOXA-51-like and subsequent sequencing were
performed to identify sequence types, as previ-
ously described by Turton et al. [17].
All A. baumannii isolates were resistant to
b-lactams, b-lactam–b-lactamase inhibitor combi-
nations, fluoroquinolones, trimethoprim–sulpha-
methoxazole, gentamicin and rifampin (Table 1).
Resistance to amikacin and tobramycin was
detected in 34 (81.0%) and 32 (76.2%) isolates,
respectively. No isolate was resistant to colistin
and minocycline. Overall, the real pandrug-resis-
tant A. baumannii isolates that were resistant to all
available antimicrobial agents [18] were not found
in this study. Although A. baumannii isolates are
fully susceptible to colistin in vitro, ten of 12
infected patients treated with colistin-based ther-
apy died. Three of five patients treated with
carbapenems combined with amikacin also died.
Accordingly, tetracycline derivatives, e.g. mino-
cycline, doxycycline and tigecycline, should be
evaluated for MDR A. baumannii infections on the
basis of in vitro susceptibility.
All imipenem-resistant A. baumannii isolates
were positive according to the modified Hodge
test, but negative according to the imipenem–
EDTA double-disk synergy test, suggesting the
production of class D or another type of carbape-
nemase. By PCR amplification and subsequent
sequencing, all A. baumannii isolates were shown
to carry both blaOXA-23 and blaOXA-51. ISAba1 was
inserted upstream of blaOXA-51 and blaOXA-23 in all
A. baumannii isolates. The mRNA expression of
both genes was confirmed by RT-PCR. In accor-
dance with the rare occurrence of metallo-
b-lactamases among A. baumannii isolates, the
A. baumannii isolates tested carried only OXA-
type carbapenemases. PCR with the primers of
blaPER-1 was performed, and 33 (78.6%) isolates
carried blaPER-1, which was responsible for resis-
tance to penicillins and cephalosporins. Resis-
tance to all aminoglycosides tested was observed
in 32 (76.2%) A. baumannii isolates, which showed
a high level of resistance to aminoglycosides
(MIC ‡256 mg ⁄L). Methylation of 16S rRNA has
emerged as a mechanism of high-level resistance
to aminoglycosides among Gram-negative bacte-
ria. The 16S rRNA methylase genes were ampli-
fied, and armA was detected in 32 isolates. PCR
results for rmtA, rmtB and rmtC were negative. Of
the currently known five methylases, ArmA
was found in A. baumannii isolates from Korea
[12], China [15] and North America [19]. As 16S
rRNA methylases confer high-level resistance to
aminoglycosides, the occurrence of ArmA in
A. baumannii can limit the clinical use of amino-
glycosides. Overall, 23 A. baumannii isolates car-
ried blaOXA-23, blaOXA-51, blaPER-1 and armA
simultaneously.
All MDR A. baumannii isolates were clustered
into one pulsotype at a similarity value of 0.90,
suggesting that they originated from a common
ancestor and clonally spread in the study hospital.
Table 1. Antimicrobial susceptibility of Acinetobacter baumannii isolates in Korea
Antimicrobial agents Resistance (mg ⁄L)
No. of isolates with MICs (mg ⁄L) of
>256 256 128 64 32 16 8 4 2 £1
Piperacillin ‡128 39 3
Carbenicillina ‡512 42
Ceftazidime ‡32 35 6 1
Cefotaxime ‡64 36 6
Cefoperazonea ‡64 42
Cefepime ‡32 2 29 4 7
Imipenem ‡16 3 35 4
Ampicillin–sulbactam ‡32 ⁄ 16 3 18 21
Piperacillin–tazobactam ‡128 ⁄ 4 3 31 8
Aztreonama ‡32 35 6 1
Amikacin ‡64 32 2 7 1
Gentamicin ‡16 42
Tobramycin ‡16 32 7 2 1
Ciprofloxacin ‡4 40 1 1
Norfloxacina ‡16 41 1
Gatifloxacin ‡8 2 35 5
Trimethoprim–sulphamethoxazole ‡4 ⁄ 76 42
Rifampinb ‡4 2 34 5 1
Minocycline ‡16 1 8 31 2
Colistin ‡4 14 28
aBreakpoints for Psedomonas aeruginosa based on the CLSI guidelines were applied [4].
bBreakpoints based on Henwood et al. [20].
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These MDR A. baumannii isolates were not genet-
ically related to the imipenem-susceptible clone
from the same hospital or the previously
described A. baumannii clones from Korea. More-
over, they were found to belong to group 1
(alleles 1-1-1 in ompA, csuE and blaOXA-51-like,
respectively) by sequence-based typing [17].
Sequence group 1 includes the representative of
European clone II, the widespread UK clones
(OXA-23 clone 1 and SE clone) and other clones
[17]. Hospital outbreaks caused by MDR A. bau-
mannii strains have been reported in Korea, but
their association with internationally spread
European clones has not been reported. In the
current study, the emergence of an MDR A. bau-
mannii strain belonging to sequence group 1 in
Korea was demonstrated.
As this MDR A. baumannii clone carrying
blaOXA-23, blaOXA-51, blaPER-1 and armA was respon-
sible for high rates of morbidity and mortality in
the infected patients, the development of alterna-
tive means of antimicrobial therapy and the
prevention of national and international spread
of this superbug should be emphasized.
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